MaxCyte ( (MXCT) ) has provided an update.
On March 11, 2025, MaxCyte announced its financial results for the fourth quarter and full year of 2024, revealing a total revenue of $8.7 million for the fourth quarter, a 45% decrease from the previous year due to one-time milestones in 2023. Despite the overall revenue decline, the company saw a 20% increase in core business revenue, highlighting growth in its main operations. MaxCyte ended 2024 with 28 active Strategic Platform License agreements, and the company remains focused on strategic initiatives and disciplined investments to enhance its position in the cell engineering solutions market.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell-engineering industry, providing platform technologies that facilitate the discovery, development, and commercialization of next-generation cell therapeutics.
YTD Price Performance: -18.52%
Average Trading Volume: 36,026
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £279.9M
See more insights into MXCT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com